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Abstract
Context: The Community Preventive Services Task Force recently recommended 
multicomponent interventions to increase breast, cervical, and colorectal cancer screening based 
on strong evidence of effectiveness. This systematic review examines the economic evidence to 
guide decisions on the implementation of these interventions.
Evidence acquisition: A systematic literature search for economic evidence was performed 
from January 2004 to January 2018. All monetary values were reported in 2016 US dollars, and 
the analysis was completed in 2018.
Evidence synthesis: Fifty-three studies were included in the body of evidence from a literature 
search yield of 8,568 total articles. For multicomponent interventions to increase breast cancer 
screening, the median intervention cost per participant was $26.69 (interquartile interval [IQI] =
$3.25, $113.72), and the median incremental cost per additional woman screened was $147.64 
(IQI=$32.92, $924.98). For cervical cancer screening, the median costs per participant and per 
additional woman screened were $159.80 (IQI=$117.62, $214.73) and $159.49 (IQI=$64.74, 
$331.46), respectively. Two studies reported incremental cost per quality-adjusted life year gained 
of $748 and $33,433. For colorectal cancer screening, the median costs per participant and per 
additional person screened were $36.63 (IQI=$7.70, $139.23) and $582.44 (IQI=$91.10, 
$1,452.12), respectively. Two studies indicated a decline in incremental cost per quality-adjusted 
life year gained of $1,651 and $3,817.
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Conclusions: Multicomponent interventions to increase cervical and colorectal cancer screening 
were cost effective based on a very conservative threshold. Additionally, multicomponent 
interventions for colorectal cancer screening demonstrated net cost savings. Cost effectiveness for 
multicomponent interventions to increase breast cancer screening could not be determined owing 
to the lack of studies reporting incremental cost per quality-adjusted life year gained. Future 
studies estimating this outcome could assist implementers with decision making.
CONTEXT
In 2015, the rates of recent cancer screening test use in the U.S. were lower (71.5%, 83.0%, 
and 62.4%) than the Healthy People 2020 target (81.1%, 93.0%, and 70.5%) for breast, 
cervical, and colorectal cancers, respectively.1 In 2016, the Community Preventive Services 
Task Force, an independent, nonfederal panel of population health experts, recommended 
multicomponent interventions (MCIs) to increase screening for breast (mammography), 
cervical (Pap test), and colorectal cancers (fecal occult blood testing [FOBT] or 
colonoscopy) based on strong evidence of their effectiveness. This systematic review 
examines the costs and economic merits of these interventions to guide implementation 
decisions. Whereas previous cancer reviews2–5 have explored the economic efficiency of 
single interventions, this is the first systematic economic review of MCIs to increase cancer 
screening.
The MCIs used to promote breast, cervical, or colorectal cancer screening include any 
combined application of two or more single intervention components or intervention 
components addressing more than one structural barrier.6 Single intervention components, 
presented in Figure 1 and defined in Appendix Table 1 (available online), are categorized 
into three broad intervention strategies6:
1. Increasing community demand for screening. This includes client reminders, 
client incentives, small media, mass media, group education, and one-on-one 
education.
2. Increasing community access to screening services. This includes reducing 
structural barriers (appointment scheduling assistance, assistance with child care, 
alternative screening hours, alternative screening locations, transportation 
assistance, language translation services, and administrative or other barriers) 
and reducing client out-of-pocket costs.
3. Increasing provider delivery of screening services. This includes provider 
assessment and feedback, provider incentives, and provider reminders.
EVIDENCE ACQUISITION
Methods (Economic Measures and Analysis)
This systematic economic review focused on studies reporting cost, cost–benefit, and cost-
effectiveness estimates. The intervention cost can provide program planners with an estimate 
of how much it would cost to implement similar interventions.7 It encompasses costs 
associated with intervention personnel, materials, and delivery of screening services and 
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other intervention-related costs.7 Owing to the variation in sample size among studies, total 
cost was standardized to per capita cost by dividing the total intervention costs by the 
number of participants who received the intervention. The cost–benefit estimate, which 
compares the monetized value of the benefits and intervention costs, is reported as the 
benefit–cost ratio8:
Intervation Benefit
Intervation Cost
The cost-effectiveness estimate represents the economic value of an intervention compared 
with an alternative.8 It is reported as an incremental cost-effectiveness ratio (ICER)8:
ΔCost
ΔEffectiveness =
Cost of Intervation ‐ Cost of Comparator
Effectiveness in Intervation Arm ‐ Effectiveness in Comparator 
The change in effectiveness in the denominator of the ICER can be measured in two ways: 
in physical units as the number of additional individuals screened or as the quality-adjusted 
life years (QALYs) gained from screening. Therefore, an ICER can be reported with an 
intermediate or final outcome. The intermediate outcome is defined as the incremental cost 
per additional person screened, which is the ratio of the change in cost versus change in 
screenings:
Cost of Intervation ‐ Cost of Comparator
# Screened in Intervation Arm ‐ # Screened in Comparator 
The final outcome is defined as the incremental cost per QALY gained, which is the ratio of 
the change in cost versus change in QALYs gained8:
Cost of Intervation ‐ Cost of Comparator
QALYs Gained in Intervation Arm ‐ QALYs Gained in Comparator 
The QALY captures both the morbidity and mortality associated with screening as the 
product of life expectancy (number of years lived) and utility (health-related quality of life).9 
The incremental cost per QALY gained was used to determine the overall cost effectiveness 
of MCIs based on an established very conservative threshold for comparison (ICER <
$50,000/QALY: cost effective).10 As medians are more robust than arithmetic means, the 
main outcomes in this review were reported in medians accompanied by interquartile 
intervals (IQIs). However, in situations with only two available estimates, means were 
reported. The analysis was completed in 2018.
Currency Conversion and Adjustments
For non-U.S. studies, foreign currencies were converted to U.S. dollars using the Purchasing 
Power Parity Index from the World Bank.11 All dollar values were adjusted for inflation to 
2016 U.S. dollars using the Consumer Price Index.12 For inflation adjustment, the starting 
year, if not specified, was assumed to be 1 year before the publication date.
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Research Questions
The study aimed to answer the following research questions:
1. What are the costs of MCIs to increase screenings for breast, cervical, and 
colorectal cancers?
2. How do the costs of MCIs compare with their monetized benefits?
3. What is the incremental cost effectiveness for MCIs? How is it influenced by the 
baseline screening rate, type of intervention strategy, and number of intervention 
components?
4. Are MCIs cost effective compared with a very conservative threshold of $50,000/
QALY?
Literature Search
The systematic literature search was performed as a two-step process: a broad search as part 
of a larger review to determine the effectiveness of these interventions and a focused search 
on economic evaluations of these interventions. The databases used for the broad search 
from January 2004 to November 2013 were PubMed, MEDLINE, Embase, CINAHL, 
PsycINFO, Cochrane Library, Web of Science, and Chronic Disease Prevention. The broad 
search was used to ensure that no relevant studies were missed during the focused search. 
The databases used for the focused economic search from January 2004 to January 2018 
were EconLit, JSTOR, Scopus, and York Centre for Reviews and Dissemination. The end 
date for the economic search was extended to get a more recent, updated yield. The search 
strategy is included in Appendix Table 2 (available online).
Inclusion Criteria
The included studies:
1. were written in English;
2. were conducted in a high-income country (identified by the World Bank)13;
3. were MCIs to increase screening through mammography (breast cancer); Pap 
tests (cervical cancer); and FOBT, fecal immunochemical testing, flexible 
sigmoidoscopy, or colonoscopy (colorectal cancer);
4. reported at least one economic outcome (cost, economic benefit, cost–benefit, 
cost effectiveness); and
5. defined sources for input parameters and modeling methods with a completed 
sensitivity analysis for studies that modeled economic outcomes.
EVIDENCE SYNTHESIS
Literature Search Yield
The economic literature search (January 2004–January 2018) identified 8,568 articles. The 
body of evidence (Figure 2) included 53 studies14–66 distributed as nine 
studies14,16,17,19–23,26 for breast cancer, six studies28–33 for cervical cancer, 33 studies34–66 
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for colorectal cancer, two studies15,25 for both breast and cervical cancers, and three 
studies18,24,27 for both breast and colorectal cancers.
Study Characteristics
A total of 40 studies14–21,24–27,29,31–33,35–38,40–42,45,46,48,50,52,54–65 were conducted in the 
U.S., and 13 studies22,23,28,30,34,39,43,44,47,49,51,53,66 were conducted in other high-income 
countries.13 The U.S. studies were distributed in the following geographic regions: 
Northeast,15,18,24,37,38,46,50,52,58,62,63 Southeast,17,18,26,27,55,64,65 Midwest,14,16,25,36,42,45,54 
Southwest,19,20,29,33,35,56,59–61 and West.21,29–32,40,41,48,57 There were non-U.S. studies 
from Japan22 and Spain23 for breast cancer; from Japan28 and Canada30 for cervical cancer; 
and from Netherlands,34,39 France,47,49,53 Hong Kong,51 South Korea,66 and Italy43,44 for 
colorectal cancer.
Most of the studies were RCTs.14–17,20–22,24,25,29–32,34–43,45–50,52–54,56–58,62,64,66 Most 
included cost-effectiveness analyses, reporting ICERs,
14–16,18,20–24,26,27,29–33,35–38,40,41,45,47,49,57,60,62,64–66
 whereas some reported only cost 
estimates.17,19,25,28,34,39,42–44,46,48,54–56,58,59,61 Only one study reported cost–benefit 
estimates.63 Of the studies reporting cost-effectiveness estimates, the majority had 
comparators that did not receive an intervention (usual-care group).
14–16,18,20–22,27,29–31,33,35–38,40,41,47,49,57,60,62,66
 Other studies had comparators that 
contained a single intervention component.23,24,26,32,45,64,65 For colorectal cancer, identified 
studies focused on increasing colorectal cancer screening through FOBT/fecal 
immunochemical testing,24,35,36,39–50,52–54,56,57,59,61,62,64–66 flexible sigmoidoscopy,55 and 
colonoscopy.18,34,37,38,51,58,60,63
Across all three cancers, the predominant intervention strategies were a combination of 
increasing both community demand and community access.15,19–33,39–61,64–66 Most of the 
studies across all three cancers had MCIs with two intervention components.
14,16,17,20,23,25–29,32,34–52,62,63,66
 Other studies contained three components,
19,22,24,33,53–56,64
 four components,18,30,31,57–59,65 five components,15,21 six components,60 
or seven components.61 For breast cancer screening, the most common intervention 
component was client reminders (30% of breast cancer MCI study arms).14–16,19–24,26,27 For 
both cervical29–32 and colorectal24,39–48,50–62,64–66 cancer screening, it was reducing 
structural barriers (36% of cervical and 35% of colorectal cancer MCI study arms). The 
most common way to reduce structural barriers was appointment scheduling assistance for 
breast cancer screening,15,18,24,26,27 transportation assistance for cervical cancer,30–32 and 
alternative screening through mailing of FOBT kits for colorectal cancer.
39–48,50–55,57,59,61,62,64–66
Intervention Costs
Breast cancer.—The median intervention cost per participant was $26.69 (IQI=$3.25, 
$113.72; 17 study arms) across all studies,14–25 $1.49 (IQI=$0.95, $12.22; five study arms) 
for interventions that increased community demand,14,16,17 and $44.83 (IQI=$4.90, $133.37; 
11 study arms) for interventions that increased community demand and community access 
(Table 1).15,19–25 The wide range for cost can be explained by the composition of 
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intervention components. MCIs with lower cost estimates paired education with client 
reminders, whereas more expensive MCIs focused on reducing structural barriers. For the 
number of intervention components, the median cost per participant was $26.69 (IQI=$1.49, 
$44.83; nine study arms)14,16,17,20,23,25 and $3.32 (IQI=$3.25, $6.48; five study 
arms)19,22,24 for two and three components, respectively. Studies with two components 
reporting higher cost estimates used monetary client incentives, tailored interventions, and 
home visits by community health workers. Studies with three components reporting lower 
cost estimates used telephone calls instead of home visits.
Cervical cancer.—The median intervention cost per participant was $159.80 (IQI=
$117.62, $214.73; ten study arms) across all studies, which all had combined strategies of 
increasing community demand and access.15,25,28–33 For two intervention components, the 
median cost per participant was $159.80 (IQI=$147.27, $168.91; six study arms).25,28,29,32 
These studies used specialized personnel to educate and screening vouchers to reduce out-
of-pocket costs.
Colorectal cancer.—The median cost per participant was $36.63 (IQI=$7.70, $139.23; 42 
study arms) across all studies.18,24,34–62 The median cost per participant was $44.07 (IQI=
$31.92, $46.83; three study arms) for interventions that increased community demand34,35 
and $30.82 (IQI=$7.27, $94.68; 33 study arms) for interventions that increased both 
community demand and community access.24,39–61 Only two studies had interventions 
aimed at increasing provider delivery with a per capita cost of $108.54 and $624.48.36,37 For 
the number of intervention components, the median cost per participant was $46.45 (IQI=
$15.07, $118.61; 24 study arms),34–52 $33.23 (IQI=$7.50, $106.49; ten study arms),
24,42,50,53–56
 and $8.91 (IQI=$7.53, $264.39; five study arms)18,57,59 for two, three, and four 
components, respectively.
Cost Benefit
An MCI to increase colonoscopy at three urban public hospitals used reminder telephone 
calls, lay health worker education, and appointment scheduling assistance by a patient 
navigator.63 The authors reported benefit–cost ratios >1.00 for two of three hospital sites.63 
No overall cost–benefit statement can be made because only one study with mixed evidence 
was identified.
Incremental Cost per Additional Person Screened Breast cancer.—Across all 
studies, the median incremental cost per additional woman screened was $147.64 (IQI=
$32.92, $924.98; ten study arms) (Table 1).14–16,20–24,26 The median incremental cost per 
additional woman screened was $147.64 (IQI=$33.54, $528.17; eight study arms) for studies 
focused on increasing both community demand and community access.15,20–24,26 The 
median incremental cost per additional person screened was $1,229.62 (IQI=$631.73, 
$1,239.44; three study arms)20,23,26 for two intervention components and $32.61 (IQI=
$18.90, $44.29; three study arms)22,24 for three intervention components. There was no 
consistent relationship between the baseline screening rate (median, 53%; IQI=32%, 69%; 
six estimates) and the incremental cost per additional woman screened.14,15,22–24,26
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Cervical cancer.—The median incremental cost per additional woman screened was 
$159.49 (IQI=$64.74, $331.46; six study arms) for all studies15,29–31 and $79.68 (IQI=
$69.72, $553.57; three study arms) for studies with two intervention components.29 There 
was no consistent relationship between the baseline screening rate (median, 63%; IQI=54%, 
76%; four estimates) and the incremental cost per additional woman screened.15,29–31
Colorectal cancer.—Across all studies, the median incremental cost per additional person 
screened was $582.44 (IQI=$91.10, $1,452.12; 15 study arms).24,35,36,40,41,48–50,52,53,62–65 
The median incremental cost per additional person screened was $582.44 (IQI=$51.27, 
$1,281.91; 11 study arms) for interventions that increased both community demand and 
community access.24,40,41,48–50,52,53,64,65 The median incremental cost per additional person 
screened was $369.18 (IQI=$42.70, $933.39; five study arms) for two intervention 
components40,41,49,50,52 and $582.44 (IQI=$76.98, $2,017.20; five study arms) for three 
intervention components.24,48,50,53,64 There was no consistent relationship between the 
baseline screening rate (median, 44%; IQI=27%, 60%; nine estimates) and the incremental 
cost per additional person screened.24,35,48–50,52,62,64,65
Incremental Cost per Quality-Adjusted Life Year Gained
Breast cancer.—No studies reporting incremental cost per QALY were identified.
Cervical cancer.—Two studies reported incremental cost per QALY gained (Table 2).32,33 
A community-based patient navigation intervention for Hispanic women in Texas aged ≥18 
years reported an ICER of $748/QALY gained.33 An intervention that used lay health 
workers to motivate Vietnamese–American women in Seattle aged 20–79 years to receive 
screening reported an ICER of $33,433/QALY gained.32 Both estimates were considered 
cost effective because they were below a very conservative threshold of $50,000/QALY. 
Analyzing the calculation of incremental cost and QALY gained could explain the difference 
in these estimates. In the study by Li et al.,33 the incremental cost was $44.90, and the 
incremental QALY gained was 0.06 years. In the study by Scoggins and colleagues,32 the 
incremental cost was $117.05, and incremental QALY gained was 0.0035 years. The 
incremental cost reported by Scoggins et al.32 was 2.6 times higher than that reported by Li 
and colleagues,33 primarily because the intervention involved home visits by lay health 
workers. The study by Scoggins et al.32 started with the assumption of having at least one 
Pap test every 3 years, and in the lifetime modeling, assumed Pap test frequency would 
improve by 8.36%. They calculated change in QALY gained by multiplying total QALYs 
gained by this improvement in Pap test frequency, resulting in a lower QALY gain (0.0035 
years) compared with the results reported in the study by Li and colleagues (0.06 years).33 
This lower QALY value (denominator) combined with the more than twofold increase in 
intervention cost (numerator), resulted in a 45-fold increase in its cost-effectiveness 
estimate.32
Colorectal cancer.—Two studies reported incremental cost per QALY gained.60,66 A 
patient navigation intervention to increase colorectal cancer screening by colonoscopy 
among Hispanic men in Texas aged ≥50 years reported a decline in incremental cost of 
$3,817/QALY gained.60 The second study was an intervention to increase colorectal cancer 
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screening by FOBT among people in Korea aged 50 years.66 In this study by Lee and Park,
66
 the authors used the standard group, who were mailed FOBT with no reminder, as the 
comparator for calculating the ICER. In the study by Wilson et al.,60 the calculated ICER 
had a comparator of no intervention (status quo). As Lee and Park66 provided a regional 
population distribution along with intervention and status quo cost and QALYs for all the 
study arms, the ICER was calculated for the targeted intervention group versus the same no 
intervention status quo, resulting in a decline in incremental cost of $1,651/QALY gained.66 
Both were modeled studies with a societal perspective and reported per capita costs and 
QALY gained for both intervention and comparator arms. The decline in incremental cost 
reported in the study by Wilson and colleagues60 was three times that in the Lee and Park66 
study, whereas the incremental QALY gained was 1.3 times higher.60,66 The negative 
incremental cost for both studies implies that QALYs increased, whereas averted healthcare 
costs were higher than the intervention costs, resulting in net cost savings. As both estimates 
are <$50,000/QALY, MCIs to increase colorectal cancer screening are cost effective. 
Additionally, the two studies showed that the QALYs gained from screening were associated 
with treatment cost savings that outweighed the intervention costs. The estimates also 
indicated that treatment cost savings were higher with screening by colonoscopy than with 
FOBT.
DISCUSSION
Summary of Findings
The median intervention cost per participant for MCIs to increase screening was $26.69 
(IQI=$3.25, $113.72; 17 study arms) for breast cancer, $159.80 (IQI=$117.62, $214.73; six 
study arms) for cervical cancer, and $36.63 (IQI=$7.70, $139.23; 42 study arms) for 
colorectal cancer. Compared with the costs for breast and colorectal cancer, the higher per 
capita cost for cervical cancer could be explained by the lower number of reported estimates, 
interventions reducing out-of-pocket costs through screening vouchers, and using 
specialized personnel for intervention delivery. Only one study reported monetized benefits, 
so no overall cost–benefit statement was made. The median incremental cost per additional 
person screened was $147.64 (IQI=$32.92, $924.98; ten study arms) for breast cancer, 
$159.49 (IQI=$64.74, $331.46; six study arms) for cervical cancer, and $582.44 (IQI=
$91.10, $1,452.12; 15 study arms) for colorectal cancer. The number of reported estimates 
used in the median calculation varied among the different types of intervention strategies 
and number of components. For breast and colorectal cancer, most studies used the same 
combined intervention strategy. For cervical cancer, all studies had the same combined 
strategy, making it difficult to compare between intervention strategies. For the number of 
components, the per capita cost was not always higher for a greater number of components 
as intuitively expected. Similarly, for three components versus two components, the 
observed ICER was lower for breast cancer and higher for colorectal cancer. The variability 
could be explained by the composition and intensity of intervention components along with 
the materials and personnel used for its delivery.
As additional screening resulting from the intervention could be related to baseline 
screening rates, the relationship between the two was examined. Intuitively, with higher 
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baseline screening rates, it might become more expensive to access the remaining hard-to-
reach populations. However, there was no consistent relationship because many studies did 
not report baseline rates, and the rates from those that did report varied widely. No studies 
reported incremental cost per QALY gained for breast cancer. MCIs to increase cervical and 
colorectal cancer screening were determined to be cost effective as there were two studies 
for each that reported incremental cost per QALY below the very conservative $50,000/
QALY threshold. Additionally, MCIs to increase colorectal cancer screening were cost-
saving, with ICERs below $0/QALY. These studies showed that QALYs gained from 
screening were associated with treatment cost savings that were greater than intervention 
costs.60,66 Furthermore, the study that used MCIs to improve screening with colonoscopy 
reported greater cost savings than the study focused on screening through FOBT. The greater 
cost savings for colonoscopy could be attributed to its use for screening, diagnosis, and 
treatment, which can lead to identification and removal of polyps at earlier stages, resulting 
in higher averted treatment costs.
Limitations
Most studies only reported incremental cost per additional person screened, which cannot be 
used for a cost-effectiveness determination owing to the lack of an existing threshold. 
Furthermore, it was challenging to compare intermediate outcomes because of the variation 
among studies for intervention strategies, number of intervention components, and number 
of reported estimates. Some studies reported incremental costs only without sufficient 
information required to ascertain the per capita intervention cost.26,27,64,65 Additionally, 
studies did not always provide a breakdown of cost for all individual intervention 
components within the MCI. As the focus of this review was on the overall intervention cost 
of MCIs, the lack of consistent cost reporting for individual intervention components did not 
hinder the analysis. For incremental cost-effectiveness analysis, all included studies were 
experimental. Most of these studies were RCTs, whereas two studies each for breast and 
colorectal cancer were quasi-experimental.23,26,63,65 Although only four of 31 estimates 
were from quasi-experimental studies, it is important to note that these studies did not have 
random assignment for intervention and comparator groups.23,26,63,65 Another limitation is 
that each modeling study had its own specific assumptions, input, and parameter values.
32,33,60,66
 However, these studies performed sensitivity analyses to assess the impact of key 
cost and effectiveness parameters and mentioned their specific input sources and parameters 
derived from literature.32,33,60,66
Evidence Gaps
The lack of studies reporting incremental cost per QALY gained for MCIs to increase breast 
cancer screening is an evidence gap that can be filled through modeling, as it is difficult to 
follow patients longitudinally to obtain actual morbidity and mortality outcomes. Another 
evidence gap is the low number of identified economic evaluation studies that focused on an 
intervention strategy to increase provider delivery of services. Further research on the 
different types of personnel used for intervention delivery could benefit implementers.
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Comparability
Both studies that reported incremental cost per QALY for cervical cancer were conducted in 
the U.S., adopted the same perspective, used similar modeling methods, and focused on a 
similarly aged target population.32,33 The main differences between the studies include 
ethnicity of target population, baseline screening rate, number of intervention components, 
intervention program length, and type of comparator.32,33 Although comparators for both 
studies32,33 were different, the control group in Scoggins et al.32 was treated similarly to the 
status quo (no intervention) comparator in the study reported by Li and colleagues33 in terms 
of ICER calculation. The authors state that the costs of the physical activity materials were 
promotional items with minimal cost, which were not included in the estimation of 
incremental costs.32 So, in essence, the incremental cost is the cost of the intervention, 
which is the same as treating the comparator control group as status quo.32 As the longevity 
and quality-of-life benefits of cervical cancer screening are seldom observed in a time 
adequate to capture lifetime impact, both studies used economic modeling methods to 
examine the long-term screening benefits. The study by Scoggins et al.32 constructed a state-
transition Markov model with yearly intervals because screening is scheduled to occur 
regularly, and the researchers wanted to project benefits of screening beyond the trial to 
lifetime perspective. The study by Li and colleagues33 used an evidence-based 
microsimulation model to assess improvements in long-term patient outcomes. These 
modeling methods were based on actual behavioral observations, incorporating knowledge 
from previous cancer decision models with parameter values based on the specific program, 
to make informed decisions. Both studies used input parameters and utility weights from 
literature derived from the U.S. population and performed sensitivity analyses. For colorectal 
cancer, the economic finding included both colonoscopy and FOBT. Although there are 
differences in screening cost, the focus of the finding is on the MCIs to increase screening. 
Both studies reporting incremental cost per QALY had the same perspective and similar 
comparators and modeling types.60,66 The differences between the studies include number 
of intervention components, program length, target population, and location.60,66 The health 
utility weights used in the non-U.S. study were derived from published studies containing 
potentially applicable sources of North American and European populations.66 Nonetheless, 
it is important to note that there are sociocultural differences in this target population.66
Implementation Considerations
Understanding the target population before implementation can be helpful. One of the cost-
effective studies focused on key factors that the target population considers when 
contemplating screening.33 Their patient navigation services leveraged behavioral 
economics principles to address decision making by focusing on sociocultural norms 
through personalized communication.33 To personalize the delivery of MCIs, personnel with 
the same ethnicity as the target population could be used during intervention delivery to 
improve participant receptiveness. One of the cost-effective studies invested in bicultural, 
bilingual Vietnamese–American women as lay health workers to reduce cultural barriers.32 
Using personnel with familiarity to the target population provides an opportunity to 
personally understand concerns, address barriers, and serve as motivators to encourage 
screening. Furthermore, demonstrating cultural competency assists in effectively delivering 
relatable motivational messages.60 Cultural competency training can be provided to 
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personnel delivering MCIs. Another consideration is behavioral variation among individuals 
from the same ethnic group based on prior screening history. For example, Vietnamese–
American women who had never been screened did not respond as favorably to home visits 
when compared with Vietnamese–American women who had been screened at least once in 
the past.32 This indicates the importance of considering behavioral (prior history) and 
sociocultural factors during implementation.
For low-income, uninsured populations, it is especially important to consider structural and 
financial barriers. One of the cost-effective studies designed MCI for a low-income, 
uninsured population by examining and addressing financial and structural barriers through 
free screening, transportation assistance, and improved access to screening locations with 
flexibility of hours.60 The MCI focused on bolstering social networks through culturally 
appropriate communication to motivate not only the target population but also their family 
and friends for support. The subsequent increase in colonoscopy screening led to more 
cancer cases being diagnosed at earlier stages, which contributed to averted healthcare 
treatment costs, improved life expectancies, and QALYs gained.60 Implementing MCIs for 
vulnerable populations can be beneficial to healthcare organizations to reach those without 
access to care and avoid future treatment costs at later stages of disease. Policymakers and 
other entities involved in implementation would likely also value MCIs’ benefits to patients.
CONCLUSIONS
Overall, MCIs to increase cervical and colorectal cancer screening are cost effective. 
Furthermore, MCIs for colorectal cancer screening have demonstrated net cost savings from 
averted healthcare costs. More economic evaluations reporting incremental cost per QALY 
gained are needed to make a cost-effectiveness determination for MCIs to increase breast 
cancer screening.
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Figure 1. 
Analytic framework.
a Interventions addressing multiple structural barriers are considered multicomponent.
b Reduced incidence may not apply to all cancers.
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Figure 2. 
Economic literature search results.
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